非医师社区卫生服务提供者主导的强化降压干预与常规诊疗对心血管疾病的影响(CRHCP):开放标签、盲法终点、整群随机试验
CRHCP为开放标签、盲法终点、整群随机试验,纳入≥40岁未治疗收缩压≥140 mm Hg或舒张压≥90 mm Hg(心血管高危或正在服用降压药者≥130/80 mm Hg)者,1:1随机326个村庄至非医师社区卫生服务提供者主导的强化降压干预或常规诊疗,随访36个月。干预组由受训非医师人员在初级保健医师监督下按简单阶梯方案启动和滴定降压药,目标收缩压<130 mm Hg、舒张压<80 mm Hg,并提供折扣或免费降压药和健康指导。干预组主要复合终点(心肌梗死、卒中、心力衰竭需住院、心血管死亡)年发生率1.62% vs 常规组2.40%(HR 0.67,95%CI 0.61-0.73;p<0.0001),心肌梗死、卒中、心力衰竭、心血管死亡和全因死亡均降低。
要点
- 干预组主要复合终点年发生率1.62% vs 常规组2.40%,HR 0.67(95%CI 0.61-0.73;p<0.0001)。
- 36个月时收缩压降幅组间净差-23.1 mm Hg(95%CI -24.4至-21.9;p<0.0001),舒张压净差-9.9 mm Hg(95%CI -10.6至-9.3;p<0.0001)。
- 全因死亡干预组低于常规组(HR 0.85,95%CI 0.76-0.95;p=0.0037),心血管死亡HR 0.70(95%CI 0.58-0.83;p<0.0001)。
- 低血压发生率干预组1.75% vs 常规组0.89%(p<0.0001)。
- 主要终点风险降低在年龄、性别、教育、降压药使用和基线心血管风险各亚组中一致。
适用人群与场景
- 年龄至少40岁,未治疗收缩压至少140 mm Hg或舒张压至少90 mm Hg者;心血管疾病高危者或正在服用降压药者收缩压至少130 mm Hg和舒张压至少80 mm Hg。
诊断标准与关键阈值
- 干预组血压目标:收缩压低于130 mm Hg,舒张压低于80 mm Hg。
处置流程与药物剂量
- 干预组由受训的非医师社区卫生服务提供者在初级保健医师监督下,按简单阶梯治疗方案启动和滴定降压药物,以达到收缩压低于130 mm Hg和舒张压低于80 mm Hg的目标。
- 干预组同时提供折扣或免费的降压药物以及健康指导。
- 安全性每6个月评估一次。
红旗征与不能漏的情况
- 低血压发生率干预组1.75% vs 常规组0.89%(p<0.0001)。
研究设计与关键结果
- 开放标签、盲法终点、整群随机试验,1:1随机326个村庄(每组163个村庄),共纳入33995名参与者,随访36个月;2018年5月8日至11月28日入组。
- 主要复合终点(心肌梗死、卒中、心力衰竭需住院、心血管疾病死亡)年发生率:干预组1.62% vs 常规组2.40%,HR 0.67(95%CI 0.61-0.73;p<0.0001)。
- 心肌梗死HR 0.77(95%CI 0.60-0.98;p=0.037);卒中HR 0.66(95%CI 0.60-0.73;p<0.0001);心力衰竭HR 0.58(95%CI 0.42-0.81;p=0.0016);心血管疾病死亡HR 0.70(95%CI 0.58-0.83;p<0.0001);全因死亡HR 0.85(95%CI 0.76-0.95;p=0.0037)。
- 36个月收缩压降幅组间净差-23.1 mm Hg(95%CI -24.4至-21.9;p<0.0001),舒张压降幅净差-9.9 mm Hg(95%CI -10.6至-9.3;p<0.0001)。
- 主要终点风险降低在年龄、性别、教育、降压药使用和基线心血管疾病风险各亚组中一致。
- 低血压发生率干预组1.75% vs 常规组0.89%(p<0.0001)。
证据类型、等级与局限
- 证据类型:开放标签、盲法终点、整群随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在≥40岁高血压患者中,由受训非医师社区卫生服务提供者在初级保健医师监督下按简单阶梯方案启动和滴定降压药、并提供折扣或免费药物和健康指导,可降低主要心血管复合终点和全因死亡。
- 主要终点风险降低在年龄、性别、教育、降压药使用和基线心血管疾病风险各亚组中一致。
- 干预组低血压发生率高于常规组(1.75% vs 0.89%;p<0.0001)。
指南或共识出处
- CRHCP试验,注册号ClinicalTrials.gov NCT03527719,发表于Lancet;资助:中国科学技术部和中国辽宁省科技计划。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention on cardiovascular disease has not been established. We aimed to test the effectiveness of such an intervention compared with usual care on risk of cardiovascular disease and all-cause death among individuals with hypertension.
METHODS: In this open-label, blinded-endpoint, cluster-randomised trial, we recruited individuals aged at least 40 years with an untreated systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg (≥130 mm Hg and ≥80 mm Hg for those at high risk for cardiovascular disease or if currently taking antihypertensive medication). We randomly assigned (1:1) 326 villages to a non-physician community health-care provider-led intervention or usual care, stratified by provinces, counties, and townships. In the intervention group, trained non-physician community health-care providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic blood pressure goal of less than 130 mm Hg and diastolic blood pressure goal of less than 80 mm Hg with supervision from primary care physicians. They also delivered discounted or free antihypertensive medications and health coaching for patients. The primary effectiveness outcome was a composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death during the 36-month follow-up in the study participants. Safety was assessed every 6 months. This trial is registered with ClinicalTrials.gov, NCT03527719.
FINDINGS: Between May 8 and Nov 28, 2018, we enrolled 163 villages per group with 33 995 participants. Over 36 months, the net group difference in systolic blood pressure reduction was -23·1 mm Hg (95% CI -24·4 to -21·9; p<0·0001) and in diastolic blood pressure reduction, it was -9·9 mm Hg (-10·6 to -9·3; p<0·0001). Fewer patients in the intervention group than the usual care group had a primary outcome (1·62% vs 2·40% per year; hazard ratio [HR] 0·67, 95% CI 0·61-0·73; p<0·0001). Secondary outcomes were also reduced in the intervention group: myocardial infarction (HR 0·77, 95% CI 0·60-0·98; p=0·037), stroke (0·66, 0·60-0·73; p<0·0001), heart failure (0·58, 0·42-0·81; p=0·0016), cardiovascular disease death (0·70, 0·58-0·83; p<0·0001), and all-cause death (0·85, 0·76-0·95; p=0·0037). The risk reduction of the primary outcome was consistent across subgroups of age, sex, education, antihypertensive medication use, and baseline cardiovascular disease risk. Hypotension was higher in the intervention than in the usual care group (1·75% vs 0·89%; p<0·0001).
INTERPRETATION: The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death.
FUNDING: The Ministry of Science and Technology of China and the Science and Technology Program of Liaoning Province, China.
参考来源
- He J, Ouyang N, Guo X, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023. PMID: 36871573. doi:10.1016/S0140-6736(22)02603-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。